StockData
Erasca, Inc. logo

Erasca, Inc. (ERAS) company profile

ERASNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$13.89−1.22 (-8.07%)

Close on Nov 17, 2026Market cap $4.86BP/E –Yield 0.00%

About Erasca

Pharmaceutical Preparations, SIC 2834

Erasca is a clinical-stage precision oncology company that discovers, develops, and commercializes targeted therapies for patients with cancers driven by the RAS/MAPK signaling pathway. The company’s modality-agnostic pipeline includes clinical-stage drug candidates such as ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor, as well as discovery-stage assets like ERAS-12, an anti-EGFR biparatopic antibody. Its therapies address multiple signaling nodes, direct RAS mechanisms, and pathway escape routes to overcome treatment resistance. Erasca designs its product candidates for individuals diagnosed with solid tumors and other malignancies associated with RAS and MAPK pathway alterations.

Erasca conducts research and clinical development internationally, with clinical trials taking place in the United States and China. The organization licenses and acquires therapeutic candidates from multiple geographic territories through partnerships with third-party pharmaceutical entities. It also maintains Erasca Ventures, an investment subsidiary targeting early-stage biotechnology firms, and supports the Erasca Foundation, a California public benefit corporation. The provided text does not state the company's headquarters location or employee headcount.

Summary of the business section of Erasca's latest annual report, written by StockData.

Company profile

Company

Legal name
Erasca, Inc.
Headquarters
San Diego, CA
Address
3115 Merryfield Row, Third Floor 92121
Phone
(858) 465-6511
Website
erasca.com
Employees
103, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, San Diego, California

Stock & identifiers

Ticker
ERAS
Exchange
Nasdaq
IPO date
Jul 16, 2021
Shares outstanding
350M, Aug 4, 2026
Public float
$316.40M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1761918
CUSIP
29479A108
ISIN
US29479A1088
FIGI
BBG00MTSR883
Share class FIGI
BBG00MTSR892
EIN
83-1217027

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jonathan E. LimChairman & CEO, Director32,355,576
Charles S. FuchsPresident, R&D–
Ebun GarnerChief Legal Officer105,076
Shannon MorrisChief Medical Officer20,000
David M. ChackoCFO and CBO279,980
Pratik S. MultaniDirector172,866
Julie HambletonDirector6,000
Valerie Denise Harding StartDirector22,000
Alexander W. CasdinDirector667,724
James Arthur BristolDirector207,500
Jean I. LiuDirector–
Michael David VarneyDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Jonathan E. Lim, M.D.
Chairman, Chief Executive Officer, and Co-Founder
$670.40K$3.14M$482.69K$10.50K$4.30M+10%
David M. Chacko, M.D.
Chief Financial Officer and Chief Business Officer
$516.70K$1.00M$248.02K$10.50K$1.78M-6%
Shannon R. Morris, M.D., Ph.D.
Chief Medical Officer
$515.00K$978.20K$247.20K$10.50K$1.75M+10%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 16, 2021
Offer price
$16.00
Securities offered
18,750,000
Gross proceeds
$300.00M
Exchange
Nasdaq
First trading day
Jul 16, 2021
First-day close
$17.43+8.9%
Lock-up ends (est.)
Jan 12, 2022

“The initial public offering price is $16.00 per share of common stock.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of February 28, 2026, we had 103 full-time employees (FTEs), 34 of whom have doctorate degrees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?